Sitting in on a set of 'low carb' sessions. First point made is that while weight loss is seen in short term studies, the long term efficacy is less clear. This study looks at using meal kits to caddies this. #EASD2026 #dedoc⁰

Sitting in on a set of 'low carb' sessions. First point made is that while weight loss is seen in short term studies, the long term efficacy is less clear. This study looks at using meal kits to caddies this. #EASD2026 #dedoc⁰

💉 #pharma #EASD2026

Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 $LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 $NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%.

Separate trials, 68-80 wk. No EloraTZP: on-drug data only.

midgardfinance.com/diabetes/

For people with single autoantibodies, genetic risk scores help tease out which people will need insulin. #EASD2026 #dedoc⁰

Dysglycaemia is very predictive for T1D in children but less so in adults unless we increase the threshold. #EASD2026 #dedoc⁰

Obesita’: il triplo agonista sperimentale Retatrutide di Lilly porta a una perdita di peso media del 20,8% e a una riduzione significativa dell’A1C nello studio TRIUMPH-2 #EASD2026

Eli Lilly and Company, azienda produttrice di tirzepatide ha annunciato oggi i risultati dettagliati dello studio…

It is also really hard to differentiate adult onset T1D from T2D using the common measures. Even antibodies drop off with age. #EASD2026 #dedoc⁰

While half of type 1 cases are diagnosed in adulthood, the rising incidence of type 2 in age washes out the proportion of type 1 cases leading to misdiagnosis #EASD2026 #dedoc⁰

👋 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐦𝐞𝐭 𝐭𝐡𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐲𝐞𝐭? 𝐂𝐨𝐦𝐞 𝐬𝐚𝐲 𝐡𝐢!

EASD members - join us for a Meet & Greet with EASD President Francesco Giorgino.

📅 𝐓𝐎𝐃𝐀𝐘, 01 Oct 2026 | 🕒 15:15 - 16:15 CEST | 📍 EASD Member Lounge

Drop by, say hello & connect with fellow members at #EASD2026!

Published in @thelancet.com

#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026

#MedSky #EndoSky

In @thelancet.com

Cardiovascular safety of #orforglipron versus insulin glargine in adults with type 2 #diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
www.thelancet.com/journals/lan...
#T2D
#EASD2026

#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social

These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.

👉 go.boehringer.com/SBqTr

#LifeForward #EASD2026

🙌 1 hour to go! See you at 10:30 at Oslo Hall for our EASD symposium on diabetes education in the AI era.
 
#EASD2026

In a phase 3, double-blind, placebo-controlled trial involving adults with obesity and type 2 diabetes, the investigational glucagon receptor–GLP-1 receptor dual agonist survodutide led to significant weight reduction. Full SYNCHRONIZE-2 trial results: https://nej.md/4yrHEMu

#EASD2026

At #EASD2026? Meet Metabolon at booth Q.03!

Diabetes is more than glucose. Discover how metabolomics can support risk assessment, patient stratification, and research into disease mechanisms and treatment response.

Stop by and tell us about your research!

Diabetes research is in Milan this week!

Follow the #dedocvoices at #EASD2026 as they share the research, technology and conversations that matter to people living with diabetes.

#Diabetes #DiabetesAdvocacy

Shukri F Mohameda & Andre Pascal Kengne comment on:
What #Mauritius teaches us about #diabetes surveillance thelancet.com/journals/lan...
#T2D #OGTT
#FREE to read w/reg (also FREE)
#EASD2026

#MedSky #EndoSky

New—Trends in prevalence of type 2 #diabetes and intermediate #hyperglycaemia in #Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study thelancet.com/journals/lan...
#T2D #OGTT
#FREE to read w/reg (also FREE)
#EASD2026

#MedSky #EndoSky

If you want to get your steps in, attend a diabetes conference #EASD2026 #dedoc⁰

🔬Happening now at #EASD2026. Clinical trial presentations exploring new approaches to #T2D & #obesity:

1️⃣ 08:30 Orforglipron | 📍Budapest Hall
2️⃣ 09:30 SMARTEST |📍 Budapest Hall
3️⃣ 09:30 SYNCHRONIZE | 📍Dublin Hall
4️⃣ 09:30 RESET for REMISSION | 📍Vienna Hall

Explore now 👉 www.easd.org/annual-meeti...